Clinical Trials /

A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer



The purpose of this study is to test the safety of a combination of an investigational WT1 vaccine and another drug called nivolumab. This is the first time that the WT1 vaccine and nivolumab are being used in combination. Also, to test the safety of a combination of an investigational NY-ESO-1 vaccine and another drug called nivolumab.

Related Conditions:
  • Fallopian Tube Carcinoma
  • Ovarian Carcinoma
  • Primary Peritoneal Carcinoma
Recruiting Status:



Phase 1

Trial Eligibility



  • Brief Title: A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
  • Official Title: A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission

Clinical Trial IDs

  • ORG STUDY ID: 15-247
  • NCT ID: NCT02737787


  • Ovarian Cancer
  • Fallopian Tube
  • Primary Peritoneal Cancer
  • Recurrent Ovarian Cancer


WT1 VaccineWT1 Vaccine and Nivolumab
NivolumabWT1 Vaccine and Nivolumab


The purpose of this study is to test the safety of a combination of an investigational WT1 vaccine and another drug called nivolumab. This is the first time that the WT1 vaccine and nivolumab are being used in combination.

Trial Arms

WT1 Vaccine and NivolumabExperimentalPatients will initially receive 6 vaccinations over 12 weeks and 7 infusions of nivolumab over 14 weeks. Toxicity assessments will be performed with each dose of vaccine, and 3 weeks after the completion of therapy at week 15. Patients who do not have disease progression at the week 15 evaluation are permitted to receive 4 additional vaccines administered approximately every 8 weeks. This maintenance vaccine course would begin at week 19.
  • WT1 Vaccine
  • Nivolumab

Eligibility Criteria

        Inclusion Criteria:

          -  Pathologic diagnosis of ovarian, fallopian tube or primary peritoneal cancer confirmed
             by pathology review at MSK.

          -  Patients will have relapsed at least once and returned to complete clinical remission
             after additional chemotherapy. Interval surgery is permitted.

          -  Complete clinical remission is defined as CA-125 within normal limits, examination and
             CT or MRI without objective evidence of disease (non specific abnormalities are
             permitted on radiologic imaging).

          -  Patients may sign screening consent during recurrence or at time of remission if they
             can start vaccine therapy within 4 months of completing chemotherapy.

          -  Testing of patient's archived (paraffin embedded, unstained slides) or freshly
             biopsied tumor nodules must be positive for WT1 protein expression. WT1 expression:
             Immunohistochemical analysis will be performed using the technique described by Dupont
             et al [58]. WT1 expression will be graded according to an adaptation of the German
             Immunoreactive Score (IRS). Only tumors with moderate to strong IRS scores (4-12) will
             be considered WT1 positive.

          -  Age ≥ 18 years

          -  Karnofsky performance status ≥ 70%

          -  Hematologic parameters: Absolute neutrophil count ≥ 1000/mcL, Platelets > 50 K/mcL.

          -  Biochemical parameters: Total bilirubin ≤ 1.5 mg/dl, AST and ALT ≤ 2.5 x upper limits
             of normal, Creatinine ≤ 1.5 mg/dl.

          -  Patient of childbearing potential must have a negative serum pregnancy test prior to
             study entry and must be practicing and effective form of birth control

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Patients with active infection requiring systemic antibiotics, antiviral, or
             antifungal treatments

          -  Patients with a serious unstable medical illness or another active cancer.

          -  Patients with a condition requiring systemic treatment with either corticosteroids
             (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14
             days of study drug administration. Inhaled or topical steroids and adrenal replacement
             doses >10mg daily prednisone equivalents are permitted in the absence of active
             autoimmune disease.

          -  Patients with known history of testing positive for human immunodeficiency virus (HIV)
             or known acquired immunodeficiency syndrome (AIDS).

          -  Patients with known active hepatitis B virus or hepatitis C virus acute or chronic

          -  Patients with active known or suspected autoimmune disease (treated hypothyroidism is
             permitted to enroll)

          -  Patients with active interstitial pneumonitis.
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:Female
Healthy Volunteers:No

Primary Outcome Measures

Measure:Dose limiting toxicity (DLT)
Time Frame:30 days
Safety Issue:
Description:The first 3 patients will be observed for 30 days before enrolling the next 7 patients. Accrual will continue as patients become available after the first 3 patients are observed for 30 days. If >2/10 DLTs are observed then the study combination will not be considered safe.


Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Active, not recruiting
Lead Sponsor:Memorial Sloan Kettering Cancer Center

Trial Keywords

  • Second or Greater Remission
  • WT1 Analog Peptide Vaccine
  • Montanide
  • GM-CSF
  • Nivolumab
  • 15-247

Last Updated